RNAC selectabio.com: Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan

Cartesian Therapeutics (RNAC) is implementing robotic systems and AI control to automate the production of RNA-based drugs. The EV/EBITDA valuation trend, which currently stands at 0.00, accompanies the company's development of anti-tumor agents. The business relies on external contractors for manufacturing and testing to avoid plant-related capital expenditures. However, the high cost of personalized medicines and a capital shortage create significant risks for R&D.

Selecta Biosciences - Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan RNAC (periode 23.11.2025 - 10.11.2026)

selectabio.com (RNAC) - rincian metrik lan laporan keuangan

- rega saham lan target rega konsensus:

Kutipan saham Cartesian Therapeutics Inc|RNAC - Rata-rata rega prakiraan

- data kapitalisasi saham perusahaan:

Biji pasar Selecta Biosciences Inc.|RNAC - Nilai Dipunlarasaken Utang lan Kas

- rincian valuasi buku bisnis:

Nilai Buku saben Saham Cartesian Therapeutics|RNAC - Aset Bersih Perusahaan|Rasio Kapitalisasi Pasar marang Nilai Buku selectabio.com|RNAC - Aset Perusahaan

- informasi babagan utang lan solvabilitas:

Utang marang Ekuitas Cartesian Therapeutics|RNAC - Utang jangka dawa marang ekuitas|Utang jangka cendhak marang ekuitas Cartesian Therapeutics, Inc.|RNAC - Utang perusahaan|Utang marang nilai buku Selecta Biosciences Inc.|RNAC - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Cartesian Therapeutics|Rasio cepet selectabio.com

- rincian asil keuangan lan kelipatan valuasi:

RNAC - Penghasilan resik perusahaan|Bathi sing dikarepake Cartesian Therapeutics|RNAC - Pangali rega marang bathi|Pangali Forward P/E Cartesian Therapeutics|RNAC - Rega marang bathi kanthi panyesuaian wutah|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Selecta Biosciences Inc.|RNAC - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Bathi resik saben saham sajrone 12 wulan pungkasan Cartesian Therapeutics|RNAC - Bathi saben saham sajrone patang kuartal pungkasan|Wutah bathi EPS kuartalan selectabio.com|RNAC - Tambahing bathi saben saham ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Cartesian Therapeutics

Ringkesan analitik perusahaan:Cartesian Therapeutics Inc (RNAC)

Produk asli Cartesian Therapeutics, Inc.

Investors must identify the fundamental drivers of asset resilience through objective financial metrics. This indicator is calculated as the ratio of total enterprise value to earnings before interest, taxes, depreciation, and amortization. The EV/EBITDA trend allows for an assessment of the company's real value, accounting for its debt load. For Cartesian Therapeutics (RNAC), this indicator confirms investment attractiveness amid high confidence in their RNA platform.

Pesaing wigati